Voit & Company’s Pfizer PFE Stock Holding History

Voit & Company’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8,421	Closed	-$339K	–	83
2019 Q1	$339K	Buy	+8,421	New	+$337K	0.36%	49

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Voit & Company's PFE Position: Q2 2019 in Review

Voit & Company sold out of Pfizer (PFE) in Q2 2019, closing a stake of 8,421 shares — an estimated $339K sold.

Voit & Company first reported a position in PFE in Q1 2019 and held it in 1 quarter. The position peaked at $339K in Q1 2019. 2,378 funds tracked by Wall St. Rank hold PFE as of Q2 2019.

Voit & Company reported no remaining Pfizer position as of Q2 2019 after selling out during the quarter.
Voit & Company sold 8,421 Pfizer shares in Q2 2019, an estimated $339K.
Voit & Company first reported a position in Pfizer in Q1 2019 and held it in 1 quarter.
Voit & Company's Pfizer position peaked at $339K in Q1 2019.
2,378 funds tracked by Wall St. Rank held Pfizer as of Q2 2019.

Based on Voit & Company's 13F filing for Q2 2019, filed 1 Aug 2019.